SCHEMBL3597232

SCHEMBL3597232

CCOC(=O)CCC1CCNCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 2/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
GNAI3 P08754 1/20 0.42
GNAO1 P09471 1/20 0.42
GNAI1 P63096 1/20 0.42
CYP1A2 P05177 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR4 Q13639 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2942254 0.98 GNAI3 (0.44) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL852008 0.90 CYP1A2 (0.46) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL1410339 0.90 SLC6A1 (0.44) TDP1ALDH1A1USP2ALOX15GNAI3
Hydrochloric Acid SCHEMBL29602469 0.88 GNAO1 (0.46) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL14173380 0.88 ALDH1A1 (0.51) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL7424483 0.87 ALDH1A1 (0.54) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL7293121 0.87 ALDH1A1 (0.54) TDP1ALDH1A1USP2ALOX15GNAI3
SCHEMBL18623243 0.87 ALDH1A1 (0.50) TDP1ALDH1A1USP2ALOX15CYP1A2
SCHEMBL8556452 0.86 GNAI3 (0.43) TDP1ALDH1A1USP2GNAI3GNAO1
Hydrochloric Acid SCHEMBL7424476 0.85 ALDH1A1 (0.52) TDP1ALDH1A1USP2ALOX15GNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-06-05 US disclosed
EP-4460496-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland DAC (IE) 2024-11-13 EP disclosed
CN-112384509-B Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-04-30 CN disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 EP disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 EP disclosed
WO-2024001839-A1 HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2024-01-04 WO disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
WO-2023131868-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2023-07-13 WO disclosed
US-6100253-A 3-(1-(3-(XANTHEN-9-YLIDENE)-1-PROPYL)PIPERIDIN-4-YL)PROPIONIC ACID, FOR EXAMPLE; TREATING NON-INSULIN DEPENDENT DIABETES, NEUROGENIC INFLAMMATION AND OBESITY; INTERFERE WITH C-FIBERS TO INHIBIT SECRETION OF INSULIN ANTAGONISING PEPTIDES NOVO NORDISK A/S (DK) 2000-08-08 US disclosed
US-6066632-A ANALGESICS; ANTIINFLAMMATORY AGENTS NOVO NORDISK A/S (DK) 2000-05-23 US disclosed
EP-0991621-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 2000-04-12 EP disclosed
US-6040318-A TREATING INSULIN RESISTANT NON-INSULIN-DEPENDENT DIABETES MELLITUS AND AGEING-ASSOCIATED OBESITY, NEUROGENIC INFLAMMATION ASSOCIATED WITH NEUROPATHY OR RHEUMATOID ARTHRITIS NOVO NORDISK A/S (DK) 2000-03-21 US disclosed
WO-1999000367-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1999-01-07 WO disclosed
EP-0398427-B1 Antirhinoviral pyridazinamines JANSSEN PHARMACEUTICA NV (BE) 1994-03-16 EP disclosed
US-5112825-A Antirhinoviral heteroamine-substituted pyridazines JANSSEN PHARMACEUTICA N.V. (BE) 1992-05-12 US disclosed
EP-0398427-A1 Antirhinoviral pyridazinamines JANSSEN PHARMACEUTICA N.V. (BE) 1990-11-22 EP disclosed
US-4357337-A PIPERIDINYLALKYL DERIVATIVES PHARMINDUSTRIE (FR) 1982-11-02 US disclosed
US-4289772-A PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179032-A1 HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE SLC2A9, SLC2A1, SLC2A8 TDP1 2394/4885ALDH1A1 745/4885USP2 2944/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 TDP1 4128/4885ALDH1A1 3733/4885USP2 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.